Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Equity Ratio (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Equity Ratio data on record, last reported at 0.96 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 11.28% year-over-year to 0.96; the TTM value through Dec 2025 reached 0.96, up 11.28%, while the annual FY2025 figure was 0.96, 11.28% up from the prior year.
  • Equity Ratio reached 0.96 in Q4 2025 per TLSI's latest filing, down from 0.73 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.25 in Q3 2023 and bottomed at 16.21 in Q2 2023.
  • Average Equity Ratio over 4 years is 2.74, with a median of 0.87 recorded in 2024.
  • The widest YoY moves for Equity Ratio: up 140.35% in 2023, down 2683.27% in 2023.
  • A 4-year view of Equity Ratio shows it stood at 8.05 in 2022, then soared by 86.34% to 1.1 in 2023, then grew by 1.82% to 1.08 in 2024, then rose by 11.28% to 0.96 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.96 in Q4 2025, 0.73 in Q3 2025, and 0.47 in Q2 2025.